Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Den Haag, Netherlands Clinical Trials

A listing of Den Haag, Netherlands clinical trials actively recruiting patients volunteers.

RESULTS

Found (125) clinical trials

Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anaemia Due to Angiodysplasias

Rationale Gastrointestinal angiodysplasias are an important cause of difficult to manage bleeding, especially in older patients. Angiodysplasias are technical challenging to manage endoscopic. Some patients are blood transfusion or iron infusion dependent due to rebleedings despite endoscopic intervention. In clinical practice we face difficulties in these patients as there is ...

Phase

4.72 miles

Learn More »

Tailoring NEOadjuvant Therapy in Hormone Receptor Positive HER2 Negative Luminal Breast Cancer.

Based on Ki67 levels after two weeks of initial letrozole treatment in postmenopausal patients with hormone receptor positive, HER2 negative, stage II/III breast cancer, patients are either advised to continue letrozole treatment (if Ki67 <1%) or will be randomized between standard chemotherapy (AC-T) or ribociclib in combination with letrozole (if ...

Phase

4.72 miles

Learn More »

Impact of Nationwide Enhanced Implementation of Best Practices in Pancreatic Cancer Care (PACAP-1)

Rationale The Dutch Pancreatic Cancer Project (PACAP) is an initiative of the Dutch Pancreatic Cancer Group and was officially launched in July 2014. PACAP is 1 of the largest nationwide collaborative outcomes registration and biobanking projects on pancreatic and periampullary cancer worldwide and includes the Dutch Pancreatic Cancer Audit (DPCA), ...

Phase N/A

4.72 miles

Learn More »

Reducing Aggression Among People With an Intellectual Disability

Rationale: The prevalence of aggression among people with an intellectual disability is high. Previous studies have demonstrated the potential of multivitamin-, mineral-, and n-3 fatty acids (n-3FA) supplementation to reduce antisocial behavior and aggression among schoolchildren and prisoners. Objective: To test the hypothesis that multivitamin-, mineral-, and n-3 FA supplementation ...

Phase N/A

4.93 miles

Learn More »

The ABSORB Bioresorbable Scaffold Below the Knee Study

The aim of this study is to evaluate the performance of a bioresorbable vascular scaffold coated with the drug Everolimus. This will be used to treat short length blockages of up to 55mm (5.5cm) in arteries below the knee. This will be performed to treat patients who have severe leg ...

Phase N/A

5.3 miles

Learn More »

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily, in addition to conventional post-AMI treatment, in reducing the occurrence of composite endpoint ...

Phase

5.3 miles

Learn More »

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

Cervarix™ or control [Al(OH)3] has been administered in the primary study NCT00294047.

Phase

5.3 miles

Learn More »

Individualized Nutritional Counselling During Chemotherapy for Colorectal Cancer (COLONUT)

The purpose is to study the effect of individualized nutritional counselling compared to usual nutritional care on cross-sectional muscle area in patients with stage IV colorectal cancer during first line chemotherapy. Secondary, effect on total lean body mass, treatment intensity, physical functioning, quality of life and survival will be studied.We ...

Phase N/A

5.3 miles

Learn More »

Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

Chemoimmunotherapy is the standard of care in first-line treatment of CLL patients without del17p or TP 53 mutation; physically fit patients are treated with fludarabine, cyclophosphamide and rituximab (FCR)1. Due to the high risk of severe neutropenias and infections with FCR, bendamustine and rituximab (BR) must be considered in patients ...

Phase

5.3 miles

Learn More »

IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma

This is a multicentre, placebo-controlled, double-blind, 1:1 randomised Phase IIb study in female hormone receptor-positive metastatic breast cancer patients. The study comprises of two stages. Stage 1 is the open-label, safety run-in stage consisting of cohort 1 and 2 to confirm the (RPTD) of IMP321 in combination with paclitaxel. Stage ...

Phase

5.96 miles

Learn More »